Premium
Systemic adjuvant therapy of breast cancer
Author(s) -
Garrett Thomas J.,
Vahdat Linda T.,
Kinne David W.
Publication year - 1997
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/(sici)1096-9098(199702)64:2<167::aid-jso16>3.0.co;2-3
Subject(s) - medicine , breast cancer , adjuvant , oncology , adjuvant therapy , disease , systemic therapy , clinical trial , chemotherapy , cancer , surgery , intensive care medicine
Systematic adjuvant therapy has improved the outcome for women with operable breast cancer. As a result, a substantial proportion of patients with this disease are candidates for adjuvant treatment. In providing a woman with recommendations for therapy, her risk of developing recurrent breast cancer needs to be assessed in relationship to the degree of benefit she will obtain from treatment. With the range of presently available treatments, an individualized approach is necessary to provide the patient with options appropriate for her own situation. For women with a high risk of recurrence despite current standard adjuvant therapies, innovative approaches with high dose chemotherapy followed by infusion of autologous hematopoietic stem cells and growth factors are being evaluated. Ongoing clinical trials will demonstrate whether or not these newer therapies result in a better outcome. J. Surg. Oncol. 64:167–172 © 1997 Wiley‐Liss, Inc.